Revealing the anti-diabetic agent in the known anti-cancer agent Bexarotene: Bexarotene-based therapy for body weight control, energy homeostasis and TIIDM:Bexarotene inhibits DNA methyltransferase 3a (Dnmt3a) expression, increases FGF21 expression, augments insulin sensitivity, increases glucose tolerance, and protects from diet-induced obesity and TIIDM, via up-regulation of its target gene, 10/May/2019, 6.44 am